Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Breast cancer roundup from ASCO 2021

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
18 Jun 2021

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

Prof John Allan - Weill Cornell Medicine, New York, USA
CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL ( Prof John Allan - Weill Cornell Medicine, New York, USA )
17 Jun 2021

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
17 Jun 2021

EHA 2021: Latest in immunotherapy for R/R multiple myeloma

Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo
EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )
17 Jun 2021

OncoAlert and ecancer ASCO roundup - Day 4 and 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 4 and 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
16 Jun 2021

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC

Prof Neeraj Agarwal - Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC ( Prof Neeraj Agarwal -  Huntsman Cancer Institute, University of Utah, Salt Lake City, USA )
15 Jun 2021

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL

Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
15 Jun 2021

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands
GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )
15 Jun 2021

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA
Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )
11 Jun 2021

CLL14: Venetoclax plus obinutuzumab in untreated CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany
CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )
11 Jun 2021

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA
Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )
10 Jun 2021

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA
AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )
10 Jun 2021